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Systemic lupus erythematosus (SLE) is a chronic systematic autoimmune disease. Current methods of diagnosing
SLE or evaluating its activity are complex and expensive. Numerous studies have suggested that neutrophil-to-
lymphocyte ratio (NLR) is closely correlated with the presence of SLE and its activity, suggesting that it may serve
as a diagnostic and monitoring indicator for SLE. Therefore, we performed a meta-analysis to systematically
assess the association between NLR and SLE.
We performed a literature search until 12 April 2019 in the PubMed, Web of Science, and China National
Knowledge Infrastructure databases. Cross-sectional studies comparing the NLR of SLE patients versus those of
healthy controls, of active versus inactive SLE patients, and of SLE patients with versus without lupus nephritis
were considered for inclusion. Mean intergroup NLR differences were estimated using standardized mean
differences and their 95% confidence intervals. Study quality was assessed using the Agency for Healthcare
Research and Quality instrument for cross-sectional studies.
Fourteen studies with 1,781 SLE patients and 1,330 healthy controls were included in this meta-analysis.
The pooled results showed that the NLR was significantly higher in SLE patients than in healthy controls,
in active SLE patients than in inactive SLE patients, and in SLE patients with lupus nephritis than in those without
lupus nephritis.
NLR may be an indicator for monitoring disease activity and reflecting renal involvement in SLE patients.
Nevertheless, more high-quality studies are warranted to further validate our findings.
KEYWORDS: Systemic Lupus Erythematosus; NLR; Lupus Nephritis; Meta-Analysis.
’ INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic systema-
tic autoimmune disease with high heterogeneity (1,2). SLE is
more prevalent in women of reproductive age than in men
(3-5). Although the etiology and pathogenesis of SLE have
not been fully elucidated, the breakdown of immune tole-
rance induced by environmental stimulation and genetic
factors is widely reported to play a core role in SLE (1,2,6,7).
The typical characteristics of SLE mainly include autoanti-
body production, aberrant complement system activation,
immune complex deposition, and chronic inflammation,
usually leading to multiple organ damage as well as diverse
clinical manifestations (1,2,6,7).
The disease activity of SLE is related to its distinct patho-
genesis and diverse clinical manifestations; thus, the treatment
of SLE should be timely adjusted according to the changes
in disease activity (2). The Systemic Lupus Erythematosus
Disease Activity Index 2000 (SLEDAI-2K) score is most
commonly applied to assess SLE disease activity (8). How-
ever, this score model incorporates both objective laboratory
testing indicators and physician evaluation parameters (8);
thus, it involves a certain degree of subjectivity. Additionally,
the SLEDAI-2K score is complex and expensive, thereby
inconvenient for clinical use. However, it holds great sig-
nificance in identifying reliable, practical, and economical
biomarkers to assist in diagnosing SLE and quantifying
the disease activity of SLE patients. The immune system
of SLE patients is abnormally activated by autoantigens,
which results in immune complex deposition and comple-
ment system activation, followed by chronic inflammation
(1,2,6,7,9). Furthermore, chronic inflammation stimulated
by environmental and genetic factors is a common char-
acteristic of autoimmune diseases including SLE (10,11).
Several inflammatory markers, such as C-reactive pro-
tein, erythrocyte sedimentation rate, and interferon, have
consistently been confirmed to be associated with SLE
progression.DOI: 10.6061/clinics/2020/e1450
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Peripheral blood neutrophil-to-lymphocyte ratio (NLR) is
widely reported to be associated with inflammatory response
and reflect the inflammatory status of many diseases (12-15).
Moreover, numerous studies have also reported that NLR
was closely related to SLE. Nevertheless, in these previous
studies, several factors including small sample sizes, different
methodologies, and a single-center setting may largely limit
the reliability of their results. Therefore, here we performed
a meta-analysis by combining the relevant data of these
previous studies to comprehensively assess the association
between SLE and NLR.
’ METHODS
This meta-analysis adhered to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses statement
(16) and received approval from the Ethics Committee of
Lanzhou University Second Hospital.
Search strategy
We performed a comprehensive literature search of the
PubMed, Web of Science, and China National Knowledge
Infrastructure (CNKI) databases for relevant articles pub-
lished up to 12 April 2019. The keywords used in the litera-
ture search included ‘‘systemic lupus erythematosus OR
SLE’’ AND ‘‘lymphocyte’’ AND ‘‘neutrophil.’’ The search stra-
tegy used in PubMed was: (((lymphocyte [Title/Abstract])
AND neutrophil [Title/Abstract])) AND ((systemic lupus
erythematosus [Title/Abstract]) OR SLE [Title/Abstract]).
We searched for only studies published in English and
Chinese since we understand only these two languages. The
references in the identified studies were manually screened to
identify other potential studies.
Inclusion and exclusion criteria
The eligible studies included in this meta-analysis met all
of the following criteria: (1) cross-sectional studies that
compared the values of NLR between patients with SLE and
healthy controls, patients with active SLE and those with
inactive SLE, or SLE patients with lupus nephritis and those
without lupus nephritis; (2) NLR data were presented as
mean ± standard deviation; (3) if overlapped patients were
enrolled in more than one studies, only the latest paper was
considered in our meta-analysis.
The exclusion criteria were as follows: (1) reviews, edito-
rials, case reports, letters, and conference abstracts; (2) dupli-
cate publications; (3) mean ± standard deviation of NLR
values not provided or could not be extracted by relevant
information; and (4) unrelated topics.
Data extraction
Two authors extracted the data independently, and any
disagreement was resolved by discussion among all authors.
The extracted data included name of first author, publication
year, country, study type, case number, mean age, sex ratio,
SLEDAI-2K score, SLE activity ratio, rate of lupus nephritis,
SLE diagnostic criteria, therapy, and mean ± standard
deviation of NLR values. The methodological quality of the
included studies was assessed using the Agency for Health-
care Research and Quality instrument for cross-sectional
studies (17). This instrument included 11 items assessed
using ‘‘YES,’’ ‘‘No,’’ or ‘‘Unclear’’: 1) Define the source of
information (survey, record review); 2) List inclusion and
exclusion criteria for exposed and unexposed subjects
(cases and controls) or refer to previous publications; 3)
Indicate time period used to identify patients; 4) Indicate
whether the subjects were consecutively enrolled if the study
was not population-based; 5) Indicate if the evaluators of the
subjective study components were masked to the patients’
other aspects; 6) Describe any assessments performed for
quality assurance purposes (e.g., test/retest of primary
outcome measurements); 7) Explain any patient exclusions
from the analysis; 8) Describe how confounding variables
were assessed and/or controlled for; 9) If applicable, explain
how missing data were handled in the analysis; 10)
Summarize patient response rates and completeness of the
data collection; and 11) Clarify what follow-up, if any, was
expected and the percentage of patients for whom incom-
plete data or follow-up were obtained. If the included studies
only presented the median and range of NLR and sample
size, we would estimate the mean ± standard deviation
value by referring to the study by Hozo et al. (18).
Figure 1 - Flow diagram of the study selection process.
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Statistical analysis
The mean NLR differences between patients with SLE and
healthy controls, patients with active SLE and those with
inactive SLE, and SLE patients with lupus nephritis and
those without lupus nephritis were calculated using the
standardized mean difference (SMD) and its 95% confidence
intervals (95% CI) and visually described using a forest plot.
When the 95% CI did not contain 0 and the SMD was simul-
taneously more than 0, the mean NLR relatively increased in
patients with SLE, those with active SLE, or those with SLE
and lupus nephritis. The chi-square test and I2 statistic were
used to assess the heterogeneity among the included studies,
while an I2 equal to or less than 50% signified no significant
heterogeneity (19). The fixed-effect model would be applied
for synthesized analysis if no significant heterogeneity
existed (p40.05) across the included studies; otherwise, a
random-effects model was applied. Publication bias was
visually assessed using a funnel plot produced from Begg’s
linear regression test, and Egger’s linear regression test was
further conducted to explore funnel plot asymmetry (20,21).
The sensitivity analysis performed by sequentially omitting
individual studies was used to explore whether the syn-
thesized results were stable and reliable, while subgroup
analyses were conducted to detect the sources of hetero-
geneity according to region and sample size. All statistical
analyses were performed by Stata 12.0 software.
’ RESULTS
Study selection
A flow chart of the study selection process is shown
in Figure 1. A total of 191 potentially records were yielded
through searches of PubMed, Web of Science, and CNKI.
Among the total records, there were 104 duplicates, which
were removed. Another 69 records were excluded owing
to being reviews, editorials, case reports, letters, unrelated
topics, or conference abstracts; as a result, 18 studies were
left for full-text review. During the full-text review process,
four studies were further excluded for lacking the data
of interest. Finally, 14 studies with 1,781 SLE patients and
1,330 healthy controls were included in this meta-analysis
(22-35).
Study characteristics
All included studies were cross-sectional studies published
between 2013 and 2019. The number of the enrolled patients
and healthy controls in the included studies ranged from
21 to 344 and 30 to 170, respectively. Among the included
studies, 11 were from China, one from Turkey, one from
Indonesia, and one from Egypt. Overall, the methodological
quality of the included studies was acceptable, although
some items of the included studies were unclear. Among the
included studies, 13 applied American College of Rheuma-
tology classification criteria (ACR) to diagnose SLE, while
the other applied ACR and Systemic Lupus International
Collaborating Clinics criteria. More information regarding
the main characteristics of the included studies is presented
in Table 1. Among the included studies, 13 compared NLR
between patients with SLE and healthy controls (Table 2),
five compared NLR between patients with active SLE and
those with inactive SLE (Table 3), and four compared NLR
between SLE patients with and those without lupus nephritis
(Table 4). Ta
b
le
1
-
M
a
in
ch
a
ra
ct
e
ri
st
ic
s
o
f
th
e
in
cl
u
d
e
d
st
u
d
ie
s.
P
a
ti
e
n
ts
w
it
h
S
LE
H
e
a
lt
h
y
co
n
tr
o
ls
S
tu
d
y
R
e
g
io
n
S
tu
d
y
ty
p
e
N
o
.
A
g
e
(M
e
a
n
±
S
D
)
S
e
x
(F
/M
)
S
LE
D
A
I
(M
e
a
n
±
S
D
)
W
it
h
a
ct
iv
it
y
(%
)
W
it
h
LN
(%
)
S
LE
d
ia
g
n
o
st
ic
cr
it
e
ri
a
T
h
e
ra
p
y
N
o
.
A
g
e
(M
e
a
n
±
S
D
)
S
e
x
(F
/M
)
N
O
S
A
yn
a
A
B
e
t
a
l.
(2
2
)
Tu
rk
e
y
R
1
0
8
3
5
.3
±
1
0
.2
1
0
0
/8
N
R
2
8
7
2
A
C
R
N
R
N
R
N
R
N
R
7
C
h
e
n
SY
e
t
a
l.
(3
2
)
C
h
in
a
R
1
1
3
3
9
.0
1
±
1
2
.2
8
1
0
5
/8
N
R
2
6
.5
N
R
A
C
R
N
R
1
2
0
3
7
.5
8
±
1
3
.6
4
1
1
2
/8
7
Li
LX
e
t
a
l.
(2
3
)
C
h
in
a
R
5
9
2
9
.4
7
±
1
2
.6
3
5
5
/4
5
.5
1
±
3
.7
6
N
R
0
N
R
N
o
1
4
9
2
8
.4
4
±
4
.4
2
1
3
2
/1
7
6
Li
u
X
Q
e
t
a
l.
(3
3
)
C
h
in
a
R
1
2
7
3
7
.8
6
±
1
5
.7
0
1
1
3
/1
4
1
4
.8
7
±
7
.8
5
N
R
N
R
N
R
N
R
1
0
3
4
1
.0
1
±
1
2
.6
0
8
7
/1
6
7
O
e
h
a
d
ia
n
A
e
t
a
l.
(2
4
)
In
d
o
n
e
si
a
R
2
1
N
R
2
1
/0
N
R
5
7
.2
6
1
.9
A
C
R
N
o
3
0
N
R
2
0
/1
0
6
Q
in
B
D
e
t
a
l.
(2
5
)
C
h
in
a
R
1
5
4
4
1
.4
4
±
1
4
.5
6
1
3
7
/1
7
8
.1
7
±
5
.6
6
N
R
6
4
.3
A
C
R
N
o
1
5
1
4
3
.5
6
±
1
3
.9
7
1
3
1
/2
0
7
Q
in
FX
e
t
a
l.
(3
4
)
C
h
in
a
R
1
0
0
N
R
5
4
/4
6
N
R
5
8
N
R
A
C
R
N
R
4
7
N
R
4
7
/2
2
6
So
li
m
a
n
W
M
e
t
a
l.
(2
6
)
E
g
yp
t
R
1
2
0
2
9
.9
3
±
8
.7
2
1
0
2
/1
8
N
R
5
0
5
0
A
C
R
N
o
3
0
2
7
.4
0
±
4
.9
7
2
1
/9
6
W
u
Y
X
e
t
a
l.
(2
7
)
C
h
in
a
R
1
1
6
N
R
9
7
/1
9
1
1
.3
9
±
6
.4
8
N
R
6
4
.6
6
A
C
R
N
o
1
3
6
N
R
1
1
1
/2
5
7
Y
a
n
g
Z
X
e
t
a
l.
(2
8
)
C
h
in
a
R
3
4
4
3
8
±
1
5
3
0
3
/4
1
N
R
N
R
N
R
A
C
R
,
SL
IC
C
N
o
1
7
0
4
5
±
1
0
1
5
1
/1
9
8
Y
o
lb
a
s
S
e
t
a
l.
(2
9
)
Tu
rk
e
y
R
5
1
3
3
±
9
.6
4
7
/4
N
R
N
R
N
R
A
C
R
N
R
5
5
4
5
.1
±
1
3
4
4
/1
1
6
Y
u
H
T
e
t
a
l.
(3
0
)
C
h
in
a
R
2
1
2
4
0
.1
9
±
1
5
.2
4
1
8
9
/2
3
1
0
.6
7
±
6
.6
3
1
5
.5
N
R
A
C
R
N
o
2
0
1
4
1
.4
5
±
1
2
.0
8
1
8
1
/2
0
8
Y
u
JL
e
t
a
l.
(3
1
)
C
h
in
a
R
1
9
4
4
0
.6
1
±
1
2
.5
0
1
7
9
/1
5
N
R
N
R
N
R
A
C
R
N
R
7
1
4
3
.2
4
±
1
3
.0
9
1
6
/1
0
7
Z
h
a
o
Y
L
e
t
a
l.
(3
5
)
C
h
in
a
R
6
2
4
1
±
9
1
0
/5
2
N
R
N
R
N
R
A
C
R
N
R
6
7
3
9
±
1
0
5
5
/1
2
6
A
C
R
,
A
m
e
ri
ca
n
C
o
ll
e
g
e
o
f
R
h
e
u
m
a
to
lo
g
y
cl
a
ss
ifi
ca
ti
o
n
cr
it
e
ri
a
;
LN
,
lu
p
u
s
n
e
p
h
ri
ti
s;
N
R
,
n
o
t
re
p
o
rt
e
d
;
R
,
re
tr
o
sp
e
ct
iv
e
;
SD
,
st
a
n
d
a
rd
d
e
vi
a
ti
o
n
;
SL
E
,
sy
st
e
m
ic
lu
p
u
s
e
ry
th
e
m
a
to
su
s;
SL
E
D
A
I,
Sy
st
e
m
ic
Lu
p
u
s
E
ry
th
e
m
a
to
su
s
D
is
e
a
se
A
ct
iv
it
y
In
d
e
x;
SL
IC
C
,
Sy
st
e
m
ic
Lu
p
u
s
In
te
rn
a
ti
o
n
a
l
C
o
ll
a
b
o
ra
ti
n
g
C
li
n
ic
s;
N
O
S,
N
e
w
ca
st
le
-O
tt
a
w
a
Sc
a
le
.
3
CLINICS 2020;75:e1450 Relationship between NLR and SLE
Wang L et al.
Synthesized analysis
Thirteen studies including 1,673 SLE patients and 1,330
healthy controls compared NLR between SLE patients and
healthy controls (23-35). We performed the synthesized ana-
lysis of these studies using a random-effects model consi-
dering the significant heterogeneity across these studies
(I2=96.5%, po0.001). The synthesized result showed that
NLR was significantly higher in SLE patients than in healthy
controls (SMD=1.43; 95% CI, 0.98–1.88) (Figure 2). Five
studies of 697 patients compared NLR between patients
with active SLE and those with inactive SLE (26,27,31,32,34).
The synthesized analysis of the five studies was also perfor-
med using a random-effects model due to the significant
heterogeneity (I2=97.0%, po0.001). The synthesized result
showed that an increased NLR was closely associated with
active SLE (SMD=2.05; 95% CI, 0.87–3.23) (Figure 3).
Additionally, four studies of 441 patients explored the
difference in NLR between SLE patients with versus without
lupus nephritis (22,23,25,26). Considering the lack of signifi-
cant heterogeneity (I2=0.0%, p=0.876), we conducted the
synthesized analysis of the four studies using a random-
effects model. The synthesized result showed that NLR was
also significantly higher in SLE patients with versus those
without lupus nephritis (SMD=0.77; 95% CI, 0.57–0.97)
(Figure 4).
Subgroup and meta-regression analysis
We performed the subgroup analysis and meta-regression
according to region and sample size to explore the source of
heterogeneity of the synthesized result of the NLR between
SLE patients and healthy controls. The subgroup analysis
results showed that significant heterogeneity still existed in
each subgroup, which suggested that region and sample size
may not be the main sources of heterogeneity (Table 5).
Moreover, the results of meta-regression by region (p=0.65)
and sample size (p=0.61) further confirmed that region and
sample size were not mainly responsible for the hetero-
geneity (Table 5). Although we failed to identify the main
sources of heterogeneity, we found that NLR was still
significantly higher in SLE patients than in healthy controls
Table 3 - Neutrophil-to-lymphocyte ratio in SLE patients with active versus inactive SLE.
Patients with active SLE Patients with inactive SLE
Study Case no. Mean SD Case no. Mean SD
Chen SY et al., 2017 30 5.52 5.15 83 3.08 2.23
Soliman WM et al., 2018 60 3.88 1.33 60 2.21 1.50
Qin FX et al., 2018 58 6.32 1.28 42 4.06 1.33
Wu YX et al., 2016 64 3.25 0.70 52 2.34 0.41
Yu JL et al., 2018 30 5.71 1.26 164 3.11 0.14
SD, standard deviation; SLE, systemic lupus erythematosus.
Table 4 - Neutrophil-to-lymphocyte ratio of SLE patients with versus without nephritis.
SLE patients with nephritis SLE patients without nephritis
Study Case no. Mean SD Case no. Mean SD
Ayna AB et al., 2017 78 5.9 5.9 30 2.6 2.5
Li LX et al., 2015 20 7.21 6.01 59 4.26 3.38
Qin BD et al., 2016 99 4.10 1.65 55 2.74 1.77
Soliman et al., 2018 60 4.27 1.74 60 2.86 1.54
SD, standard deviation; SLE, systemic lupus erythematosus.
Table 2 - Neutrophil-to-lymphocyte ratio of SLE patients versus healthy controls.
Patients with SLE Healthy controls
Study Case number Mean SD Case number Mean SD
Chen SY et al. (32) 113 4.01 3.65 120 1.95 0.85
Li LX et al. (23) 59 4.26 3.38 149 2.00 0.76
Liu XQ et al. (33) 127 3.08 2.46 103 1.63 0.50
Oehadian A et al. (24) 21 4.24 2.48 30 1.65 0.96
Qin BD et al. (25) 154 3.61 2.04 151 1.82 0.49
Qin FX et al. (34) 100 4.94 2.11 47 1.47 1.01
Soliman WM et al. (26) 120 3.16 1.00 30 1.21 0.21
Wu YX et al. (27) 116 2.77 0.38 136 1.64 0.13
Yang ZX et al. (28) 344 3.05 2.70 170 1.72 0.75
Yolbas S et al. (29) 51 2.90 4.15 55 1.7 1.13
Yu HT et al. (30) 212 3.66 1.91 201 1.99 0.49
Yu JL et al. (31) 194 3.61 0.37 71 2.80 0.14
Zhao YL et al. (35) 62 2.59 2.55 67 1.63 0.87
SD, standard deviation; SLE, systemic lupus erythematosus.
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in each subgroup (Table 5), indicating that our overall syn-
thesized results were robust. Considering that the number of
eligible studies was limited, we did not perform a subgroup
analysis of the synthesized results of the relationship
between NLR and disease activity as well as NLR and lupus
nephritis.
Sensitivity analyses and publication bias
To assess the stability of our synthesized results, a
sensitivity analysis was performed by sequentially omitting
individual studies and checking the consistency of the
overall effect estimate. The results showed that the overall
effect estimates of the relationship between NLR and SLE,
NLR and disease activity, and NLR and lupus nephritis did
not significantly change when any individual study was
omitted (Figure 5A-5C). The publication bias evaluation was
performed by the Egger’s test and described graphically
using the funnel plot produced from Begg’s test. In our meta-
analysis, the funnel plot was basically symmetrical and the
p value of Egger’s test was40.05, suggesting that there was
Figure 2 - The neutrophil-to-lymphocyte ratio was significantly higher in systemic lupus erythematosus patients than in healthy
controls. SMD, standardized mean difference.
Figure 3 - An increased neutrophil-to-lymphocyte ratio was closely associated with active systemic lupus erythematosus. SMD,
standardized mean difference.
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no significant publication bias in the synthesized result
comparing NLR between SLE patients and healthy controls
(Figure 5D). Therefore, our overall synthesized results were
stable and reliable. Considering that the number of eligible
studies was less than 10, we did not perform a publication
bias assessment for the synthesized result about the relation-
ship between NLR and disease activity as well as NLR and
lupus nephritis.
’ DISCUSSION
To our knowledge, no prior meta-analysis specifically
assessed the association between SLE and NLR. Although
numerous studies have reported that NLR was closely
related to SLE, several factors including small sample sizes,
different methodologies, and single-center settings may
largely limit the reliability of their results regarding the
association between SLE and NLR. Therefore, here we
performed a meta-analysis by combining relevant data of
these previous studies to comprehensively assess the asso-
ciation of SLE with NLR. In this meta-analysis, our overall
synthesized results showed that NLR was significantly
higher in SLE patients than in healthy controls, in patients
with active versus inactive SLE, as well as in SLE patients
with versus without lupus nephritis. Furthermore, our
subgroup and sensitivity analyses demonstrated the robust-
ness and reliability of these overall synthesized results.
Chronic inflammation stimulated by environmental and
genetic factors is a common characteristic in most auto-
immune diseases including SLE (10,11). The immune system
of SLE patients is aberrantly activated by autoantigens,
resulting in immune complex deposition, complement
system activation, and chronic inflammation (1,2,6,7). Addi-
tionally, several inflammatory markers, such as C-reactive
protein, erythrocyte sedimentation rate, and interferon, are
positively associated with SLE progression. Therefore, there
is a strong relationship between chronic inflammation and
SLE. The inflammatory response is always accompanied by
an increased release of many cytokines and chemokines,
which are proven to intensify the immunoreaction and
largely contribute to the pathogenesis of SLE (36-39). In
particular, white blood cells (WBCs) are involved in the
secretion of the cytokines and chemokines, which in turn
activate these WBCs (40,41). Circulating WBCs and their
Table 5 - Subgroup analysis and meta-regression of the relationship between NLR and SLE.
Heterogeneity Meta-regression
Stratified factors No. of studies Pooled SMD (95% CI) I2 (%) p value Tau2 Adj R2 (%) p value
Publication year 1.07 -6.24 0.58
42017 4 1.64 (0.96–2.32) 97 o0.01
p2017 2 1.30 (0.70–1.91) 95.1 o0.01
Sample size 1.08 -6.78 0.61
np214 6 1.26 (0.69–1.83) 91.5 o0.01
n4214 7 1.58 (0.90–2.25) 97.9 o0.01
Region 1.08 -7.34 0.65
China 10 1.46 (0.94–1.98) 97.10% o0.01
Indonesia 1 1.48 (0.85–2.11) - -
Egypt 1 2.16 (1.69–2.63) - -
Turkey 1 0.40 (0.02–0.79) - -
CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; SLE, systemic lupus erythematosus; SMD, standardized mean difference.
Figure 4 - The neutrophil-to-lymphocyte ratio was significantly higher in systemic lupus erythematosus patients with lupus nephritis
than in those without it. SMD, standardized mean difference.
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classification counts will change, typically leading to lym-
phopenia and neutrophilia, in the presence of systemic
inflammation (42,43). NLR is closely associated with most
common inflammatory biomarkers, such as C-reactive
protein and erythrocyte sedimentation rate (44-49). A grow-
ing body of evidence suggests that NLR may act as excellent
indicator of inflammation status in various diseases, such as
Crohn’s disease (49), cancer (50,51), infection (52,53), and
rheumatic diseases (54-56). Moreover, numerous studies also
reported that NLR was closely related to inflammatory
response and SLE disease activity (23-35). Consistent with
these previous studies, in this meta-analysis, we further
demonstrated a close correlation of NLR with disease acti-
vity and lupus nephritis in SLE patients. NLR can be easily
measured, is simple, is rapidly reproducible, and is an eco-
nomical biomarker. It is noteworthy that NLR has higher
stability and reliability than individual blood cell parameters,
since any individual blood cell parameter is easily affected by
many factors such as dehydration, overhydration, and discre-
pancies in blood specimen handling (57,58). Therefore, NLR
could be a dependable indicator for monitoring disease
activity and reflecting renal involvement in SLE patients.
Several limitations of our meta-analysis should be ser-
iously considered when interpreting our findings. First, there
was significant heterogeneity. Although we performed the
subgroup analysis and meta-regression according to sample
size and region, we failed to identify the sources of hetero-
geneity. The differences in clinical complications, disease
activity, disease duration, and therapies of SLE patients may
cause significant clinical heterogeneity. Second, most of the
included studies were from China; thus, it remains unclear
whether our findings could be generalized to other popula-
tions, especially western countries. Third, our meta-analysis
showed close associations of NLR with the presence of SLE,
active SLE, or lupus nephritis. However, no relevant data in
any of the included studies could be extracted for a synthe-
sized analysis of the sensitivity and specificity of NLR for
diagnosing SLE, disease activity, and lupus nephritis. Fourth,
all included studies were retrospective and cross-sectional,
which may have caused a degree of bias. Besides, due to
design principles, a cross-sectional study cannot be used to
analyze whether there is a causal correlation between a risk
factor and a disease or its progression. Thus, the current
study cannot identify whether NLR is a potential risk factor
for SLE development. Certainly, cross-sectional studies could
reflect a simple association of NLR with SLE at some point in
time, suggesting that results from cross-sectional studies may
help to explore the value of NLR in assisting the diagnosis
and surveillance of SLE. Evidence from cross-sectional
studies is weak; thus, more high-quality studies (prospective
cohort or randomized) are required to further validate the
association between NLR and SLE. Fifth, only studies pub-
lished in English and Chinese were considered in this
meta-analysis, with studies published in other languages
excluded, which may also result in a degree of bias. Sixth,
although this meta-analysis combined data of the published
studies on this topic, the total sample size was still insufficient,
which may affect the reliability of the combined results. Finally,
any diagnostic biomarker should be evaluated for sensitivity
and specificity. However, we did not perform a meta-analysis
of the accuracy tests to assess the sensitivity and specificity of
NLR for diagnosing SLE, active SLE, or lupus nephritis since
Figure 5 - Sensitivity analysis of the relationship between neutrophil-to-lymphocyte ratio (NLR) and systemic lupus erythematosus (A),
NLR and disease activity (B), and NLR and lupus nephritis (C). Begg’s funnel plot used to assess potential publication bias in this meta-
analysis (D). SMD, standardized mean difference.
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we could not extract available data from the eligible studies.
That is, the current study only suggested simple correlations
between NLR and SLE, active SLE, or lupus nephritis and
could not determine the diagnostic value of NLR. Hence,
further studies are needed to validate the clinical value of
NLR for diagnosing SLE, active SLE, or lupus nephritis.
In conclusion, this meta-analysis demonstrated that NLR
was closely associated with SLE, suggesting that it may be a
promising indicator for monitoring disease activity and
reflecting renal involvement in SLE patients. However, more
high-quality studies with large sample sizes are needed to
further confirm our findings.
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